Evidence-Based Approach to the Introduction of Positron Emission Tomography in Ontario, Canada
- 20 November 2009
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (33) , 5607-5613
Abstract
Purpose The uptake of new health care technologies is usually driven by industry promotion, physician interest, patient demand, and institutional ability to acquire the technology. The introduction of positron emission tomography (PET) scanning in the province of Ontario, Canada, followed a different path. Methods The Ontario provincial government, through its Ministry of Health and Long-Term Care, commissioned a systematic review of the literature. When this found only weak evidence that PET has a positive impact on clinical outcomes, the Ministry introduced a provincial PET evaluation program to close the evidence gap. Results This article describes the challenges encountered establishing the PET evaluation program. These included the design and conduct of the initial clinical trials, the establishment of a PET cancer registry, standardizing how PET scans were performed and reported, and gaining acceptance by health professionals for the evaluative program. Conclusion The proliferation of health technologies is a key driver of increasing health care costs. The Ontario approach to the introduction of PET is a model worth consideration by health systems seeking to ensure that they receive value for money based on a strong evidentiary base when introducing new health technologies.Keywords
This publication has 20 references indexed in Scilit:
- Medicare's Coverage With Evidence Development: A Policy-Making Tool in EvolutionJournal of Oncology Practice, 2007
- The National Oncologic PET Registry: Expanded Medicare Coverage for PET Under Coverage with Evidence DevelopmentAmerican Journal of Roentgenology, 2007
- Federal Initiatives To Support Rapid Learning About New TechnologiesHealth Affairs, 2007
- Coverage Options For Promising Technologies: Medicare’s ‘Coverage With Evidence Development’Health Affairs, 2006
- Traditional Versus Up-Front [18F] Fluorodeoxyglucose–Positron Emission Tomography Staging of Non–Small-Cell Lung Cancer: A Dutch Cooperative Randomized StudyJournal of Clinical Oncology, 2006
- Positron emission tomography in uro-oncologyCancer Imaging, 2005
- Randomized Controlled Trial of the Role of Positron Emission Tomography in the Management of Stage I and II Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe EmphysemaNew England Journal of Medicine, 2003
- Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative reviewThe Lancet Oncology, 2001
- Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucoseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996